BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research.
BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation dose-dependently in various human PCa cell lines[1].
BKIDC-1553 (20 mg/kg, p.o.,3 times weekly for 4 weeks) decreases tumor growth after 5 weeks in LuCaP 35 human PCa patient-derived xenograft mice [1].
References:
[1]. Uo T, et al. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355.